Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Brief: Xvivo's Strategy For Period 2023-27 Has Been Updated

Sept 21 (Reuters) - Xvivo Perfusion AB  XVIVO.ST :
    * STRATEGY FOR PERIOD 2023 - 2027 HAS BEEN UPDATED AND
BUILDS ON
FIVE FOCUS AREAS; MARKET LEADER ABDOMINAL; CHANGING PARADIGM OF
HEART PRESERVATION; BECOMING PREFERRED PARTNER IN TRANSPLANT
PROCESS; ACCELERATING MARKET LEADERSHIP LUNGS; AND NEW MARKET
EXPANSION
    * SHARPENS ITS PROFITABILITY AMBITIONS AND SHALL REACH AN
EBIT-MARGIN OF AT LEAST 20 % AND AN EBITDA-MARGIN OF AT LEAST 30
% DURING STRATEGY PERIOD

Source text for Eikon:  ID:nMFNbCKdZ 
Further company coverage:  XVIVO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Xvivo Perfusion AB

See all news